Retrospective analyses of CHOPE plus L-asparaginase regimen in treatment of T-cell lymphoma

• Published in: Beijing da xue xue bao. Journal of Peking University. Yi xue ban Vol. 48; no. 5; p. 841
• Main Authors: Wan, W L, Wang, J, Zhu, M X, Zhang, W, Ke, X Y
• Format: Journal Article
• Language: Chinese
• Published: China 18.10.2016
• Subjects: Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Asparaginase - therapeutic use; Comparative Effectiveness Research; Cyclophosphamide - therapeutic use; Doxorubicin - therapeutic use; Etoposide - therapeutic use; Humans; Lymphoma, Extranodal NK-T-Cell - drug therapy; Lymphoma, Extranodal NK-T-Cell - mortality; Lymphoma, T-Cell - drug therapy; Lymphoma, T-Cell - mortality; Prednisone - therapeutic use; Prognosis; Remission Induction - methods; Retrospective Studies; Survival Rate; Treatment Outcome; Vincristine - therapeutic use
• ISSN: 1671-167X

To investigate prognostic factors of the T-cell non-Hodgkin's lymphoma (T-NHL), and to study the clinical efficacy of CHOPE plus L-asparaginase(L-ASP) regimen for T-NHL. Retrospective analyses were made of 61 T-NHL patients who were treated from July 2007 to August 2013. Randomly divided into two groups CHOPE and CHOPE+L group(Based on CHOPE, added with L-ASP on the 1st, 3rd, 5th, 7th, 9th and 11th day). Of the 61 patients evaluatd with the median survival was 22 (3-65) months,the complete remission rate was 52.50%, the partial remission rate 29.51%, and the response rate 80.01%. The complete remission rate was 57.89%, and the patial remission rate 84.21% in CHOPE+L and the complete remission rate 43.48%, the response rate 78.26% in CHOPE, respectively (both P>0.05). The 1-, 2-, and 5-year overall survival rates were 91.0%, 87.6% and 65.7% respectively (P>0.05). But the overall survival rate in CHOPE+L was significantly higher than that in CHOPE group in extranodal NK/T-cell lymphoma, nasal type (ENKTCL) (P<0